These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17968817)

  • 21. Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
    Rotger M; Telenti A
    Eur J Clin Pharmacol; 2008 Apr; 64(4):335-6. PubMed ID: 18188549
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
    Penzak SR; Kabuye G; Mugyenyi P; Mbamanya F; Natarajan V; Alfaro RM; Kityo C; Formentini E; Masur H
    HIV Med; 2007 Mar; 8(2):86-91. PubMed ID: 17352764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
    Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
    Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.
    Nolan D; Phillips E; Mallal S
    Clin Infect Dis; 2006 Feb; 42(3):408-10. PubMed ID: 16392090
    [No Abstract]   [Full Text] [Related]  

  • 25. Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism.
    Garcia-Diaz A; Lok CB; Madge S; Booth C; Tyrer M; Bonora S; Mahungu T; Owen A; Johnson M; Geretti AM
    J Antimicrob Chemother; 2008 Dec; 62(6):1188-90. PubMed ID: 18786939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful genotype-tailored treatment with small-dose efavirenz.
    Gatanaga H; Oka S
    AIDS; 2009 Jan; 23(3):433-4. PubMed ID: 19188761
    [No Abstract]   [Full Text] [Related]  

  • 27. Efavirenz and psychosis: is there a link?
    Manning TG
    Aust N Z J Psychiatry; 2012 Jul; 46(7):687-8. PubMed ID: 22735641
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
    Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
    Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature.
    Torno MS; Witt MD; Saitoh A; Fletcher CV
    Pharmacotherapy; 2008 Jun; 28(6):782-7. PubMed ID: 18503405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
    ter Heine R; Scherpbier HJ; Crommentuyn KM; Bekker V; Beijnen JH; Kuijpers TW; Huitema AD
    Antivir Ther; 2008; 13(6):779-87. PubMed ID: 18839779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does tenofovir influence efavirenz pharmacokinetics?
    Rotger M; Colombo S; Furrer H; Décosterd L; Buclin T; Telenti A
    Antivir Ther; 2007; 12(1):115-8. PubMed ID: 17503755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
    Cabrera Figueroa S; Fernández de Gatta M; Hernández García L; Domínguez-Gil Hurlé A; Bustos Bernal C; Sepúlveda Correa R; García Sánchez MJ
    Ther Drug Monit; 2010 Oct; 32(5):579-85. PubMed ID: 20720517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz intoxication due to a new CYP2B6 constellation.
    Anagnostopoulos A; Rotger M; Aouri M; Kuster SP; Telenti A; Décosterd LA; Günthard HF
    Antivir Ther; 2013; 18(5):739-43. PubMed ID: 23640958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Slow efavirenz metabolism genotype is common in Botswana.
    Gross R; Aplenc R; Tenhave T; Foulkes AS; Thakur R; Mosepele M; Barrett JS; Flexner C; Strom BL; Bisson G
    J Acquir Immune Defic Syndr; 2008 Nov; 49(3):336-7. PubMed ID: 18978480
    [No Abstract]   [Full Text] [Related]  

  • 35. Efavirenz-induced psychosis.
    de la Garza CL; Paoletti-Duarte S; García-Martín C; Gutiérrez-Casares JR
    AIDS; 2001 Sep; 15(14):1911-2. PubMed ID: 11579266
    [No Abstract]   [Full Text] [Related]  

  • 36. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons.
    Tong K; He ML; Lin CK; Guo L; Kung HF; Sung JJ; Lee SS
    Clin Infect Dis; 2006 Aug; 43(4):541-2; author reply 542-4. PubMed ID: 16838248
    [No Abstract]   [Full Text] [Related]  

  • 38. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Back DJ; Owen A; Khoo SH
    Clin Pharmacokinet; 2006; 45(2):213-4; author reply 214-5. PubMed ID: 16485918
    [No Abstract]   [Full Text] [Related]  

  • 39. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient.
    Nijhawan AE; Zachary KC; Kwara A; Venna N
    AIDS Read; 2008 Jul; 18(7):386-8, C3. PubMed ID: 18655316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.
    Cabrera Figueroa S; Iglesias Gómez A; Sánchez Martín A; de la Paz Valverde Merino M; Domínguez-Gil Hurlé A; Cordero Sánchez M
    Clin Drug Investig; 2010; 30(6):405-11. PubMed ID: 20441246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.